NDAINTRA-ARTERIALSOLUTION
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ABLYSINOL (alcohol) by Gen Pharmaceuticals is intra-arterial catheter into a target septal vessel, which causes the hypertrophied septum to thin. First approved in 2018.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ABLYSINOL is an intra-arterial alcohol solution approved in June 2018 for septal hypertrophy reduction via targeted vessel catheterization. The drug works by delivering alcohol directly into a hypertrophied septum via intra-arterial injection, causing the affected tissue to thin. It represents a specialized interventional approach to a structural cardiac condition.
Peak
Product is in peak commercial phase with moderate competitive pressure (30), suggesting stable demand but limited growth opportunity and modest team expansion.
Mechanism of Action
intra-arterial catheter into a target septal vessel, which causes the hypertrophied septum to thin.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Daridorexant for Alcohol Use Disorder
Started Jan 2027
150 enrolled
Alcohol Use Disorder
High-Protein Diet for Improving Alcoholic Fatty Liver Disease
Started Jul 2026
72 enrolled
Alcohol-associated Fatty Liver Disease
Mechanisms of Cannabidiol and Sleep in the Context of Alcohol Use
Started Jul 2026
58 enrolled
SleepAlcohol Misuse
Endotoxin Exposure to Examine the Role of Inflammation in Alcohol Use
Started Jun 2026
64 enrolled
Alcohol Use DisorderInflammatory ResponseCraving
Cannabidiol and Alcohol Use Disorder Phenotypes
Started Mar 2026
150 enrolled
Alcohol Use Disorder
Worked on ABLYSINOL at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.